Pre Procedural High Serum Visfatin and Tumor Necrosis Factors "Alpha" Might Predict Recurrent Atrial Fibrillation After Catheter Ablation
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 117
- 试验地点
- 1
- 主要终点
- Recurrent Atrial Fibrillation
研究概览
简要总结
Evaluation of the predictive value of serum levels of adipocytokines and primary phase reactant for recurrent atrial fibrillation (RAF) after catheter ablation in 26 patients had persistent and 91 patients had paroxysmal AF. During 12-m follow-up, 41 patients had RAF (35%). Patients had RAF were significantly older, had significantly higher BMI, lower ejection fraction and wider maximal left atrial diameter (LAD). Serum hs-CRP, IL-6, TNF-α, visfatin, and adiponectin levels were significantly higher in patients developed. Elevated serum levels of TNF-α, visfatin and adiponectin are a significant positive predictors for RAF.
详细描述
Objectives: Estimation of serum levels of visfatin, adiponectin, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hs-CRP) in patients had atrial fibrillation (AF) resistant to medical treatment and assigned to catheter ablation (CA) to evaluate these biomarkers as predictors for recurrent AF (RAF).
Patients & Methods: 117 patients; 26 patients had persistent and 91 patients had paroxysmal AF underwent had clinical and echographic evaluations and gave blood samples for ELISA estimation of serum levels of studied cytokines. CA was performed through isolation of all pulmonary veins according to the stepwise procedure of ablation. Patients were re-evaluated every three months till 12-m follow-up for post-procedural RAF.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 50 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Symptomatic paroxysmal or persistent AF that was resistant to medical acceptable daily dose therapy in patients who were free of exclusion criteria and accepted to sign the written fully informed consent to undergo CA and to give pre-procedural blood samples.
排除标准
- •History of the presence of longstanding persistent or permanent AF,
- •myocardial infarction, acute coronary syndrome (ACS),
- •significant heart failure (NYHA3),
- •dilated or hypertrophic cardiomyopathy,
- •left ventricular ejection fraction (LVEF)< 35%, congenital pathologies,
- •significant valvular heart disease,
- •pulmonary embolism,
- •venous thrombosis,
- •intracardiac thrombus or inability to take warfarin or other oral anticoagulants,
- •hepatic or renal insufficiency,
- •acute inflammatory states (sepsis, chronic obstructive pulmonary disease in acute phase),
- •autoimmune pathologies.
结局指标
主要结局
Recurrent Atrial Fibrillation
时间窗: 12 months
Recurrent Atrial Fibrillation after Catheter ablation
次要结局
未报告次要终点
研究者
Amr Fayez Al-kassas
lecturer of Cardiology
Tanta University